Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease

Last updated: February 19, 2025
Sponsor: Fundación de investigación HM
Overall Status: Active - Recruiting

Phase

1

Condition

Dyskinesias

Parkinson's Disease

Treatment

Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area

Clinical Study ID

NCT06840678
1715-GHM
  • Ages 18-80
  • All Genders

Study Summary

This is a pilot open study to test the hypothesis that home-based transcranial static magnetic field stimulation (tSMS) of the supplementary motor area is safe and feasible to modulate corticostriatal activity in patients with Parkinson's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • idiopathic Parkinson's disease (Brain Bank criteria)

  • optimal clinical response to dopaminergic medication (>30% MDS-UPDRS-IIIimprovement)

Exclusion

Exclusion Criteria:

  • MRI-incompatible metal objects in the body (e.g. cardiac pacemakers)

  • presence of levodopa-induced dyskinesias

  • other main neuropsychiatric co-morbidity

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area
Phase: 1
Study Start date:
October 01, 2022
Estimated Completion Date:
August 31, 2025

Connect with a study center

  • HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales

    Móstoles, Madrid 28938
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.